secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2025-12-04T23:59:59+00:00
Accession:  0001837607-25-000088
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma posts corporate presentation with biosimilar pipeline update
---------------------------------------------------------------------------

- Presentation dated December 2025 highlights fresh data and new capital for full-label biosimilar approval.
- Company emphasizes simplified structure to accelerate development of lead molecule.
- No specific clinical or financial figures were disclosed in the furnished presentation excerpt.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760725000088/0001837607-25-000088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760725000088/aeon-20251204x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-25-000088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer